Organised nationwide breast cancer screening programme was introduced in Hungary in 2002

Imre Boncz

Zwahlen and colleagues published an excellent paper on the currently available scientific evidences and practical problems of breast cancer screening with mammography [1]. This article, in addition to its medical professional values, can be considered a high quality policy paper for countries considering introducing a nationwide breast cancer screening programme financed from public resources. Several countries (UK, Sweden, Australia, Canada, Finland, France, Iceland, Israel, Luxembourg, Netherlands) are listed in the paper as having nationwide breast cancer screening programme. Hungary is missing from the list because at the time when Zwahlen published his paper there were no publications in the international scientific literature on the Hungarian breast screening programme. We would like to provide some information on this.

Due to the fact that breast cancer represents large burden and public health challenge for the Hungarian society [2, 3], a pilot breast screening programme was established in Hungary in 1995 financed partly from a loan from the World Bank. The National Health Insurance Fund Administration (Országos Egészségbiztosítási Pénztár, OEP), the sole health care financing agency in Hungary, carried out and published a health economics analysis on the cost-effectiveness of breast cancer screening. The cost of one life year saved varied between CHF 1,597 (1057 EUR, 946 USD) and CHF 4,984 (3299 EUR, 2955 USD) in 2001 [4]. After evaluating the results of the pilot screening projects, the Hungarian government decided on the introduction of a nationwide organized breast cancer screening programme, which started in January 2002. Women between the age of 45–65 years are invited to mammography screening by a personal letter, a two years screening interval is applied and two-view mammograms (the mediolateral oblique and a craniocaudal views) and double readings are standard. The cost of mammography screening and travelling costs for women are fully reimbursed by the National Health Insurance Fund Administration.

The coverage, calculated as the proportion of women resident who have had a mammogram at least once in the previous two years, more than doubled from 25.85% in 2000–2001 before the nationwide programme to 53.46% in 2002–2003 following the introduction of the organized nationwide programme [5]. The Hungarian breast cancer screening programme is under continuous monitoring and evaluation. Preliminary data show that usual performance indicators of the Hungarian programme are comparable with the values of other countries [6], although in order to realize the potential benefit of reducing mortality, participation rate has to be increased.

References

Correspondence:
Imre Boncz, MD, MSc
Department of Health Policy
National Health Insurance Fund Administration (OEP)
1139 Budapest, Váci ut 73/A. Hungary
E-Mail: boncz.i@oep.hu

Financial support: none.
The many reasons why you should choose SMW to publish your research

**What Swiss Medical Weekly has to offer:**

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

**Editorial Board**

Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
  (Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

**International Advisory Committee**

Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

---

**Impact factor Swiss Medical Weekly**

![Impact factor chart](chart.png)

**All manuscripts should be sent in electronic form, to:**

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch